Fusen Pharmaceutical Company Limited (1652.HK)
HKD 0.81
(-2.41%)
HKD 0.81
(-2.41%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 309.26 Million CNY | 208.42% |
| 2022 | 100.27 Million CNY | -37.18% |
| 2021 | 159.62 Million CNY | 261.99% |
| 2020 | -98.53 Million CNY | 18.59% |
| 2019 | -121.04 Million CNY | 67.38% |
| 2018 | -371.1 Million CNY | -347.0% |
| 2017 | -83.02 Million CNY | -123.3% |
| 2016 | 356.28 Million CNY | -52.73% |
| 2015 | 753.69 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 345.12 Million CNY | 0.78% |
| 2024 Q1 | 345.12 Million CNY | 11.59% |
| 2023 Q1 | 213.41 Million CNY | 112.83% |
| 2023 FY | 309.26 Million CNY | 208.42% |
| 2023 Q4 | 309.26 Million CNY | -1.13% |
| 2023 Q3 | 312.78 Million CNY | 45.34% |
| 2023 Q2 | 215.2 Million CNY | 0.84% |
| 2022 Q3 | 102.77 Million CNY | -55.74% |
| 2022 FY | 100.27 Million CNY | -37.18% |
| 2022 Q2 | 232.19 Million CNY | 0.91% |
| 2022 Q1 | 230.1 Million CNY | 44.16% |
| 2022 Q4 | 100.27 Million CNY | -2.43% |
| 2021 Q1 | 101.59 Million CNY | 203.1% |
| 2021 Q3 | 167.39 Million CNY | 63.42% |
| 2021 Q4 | 159.62 Million CNY | -4.64% |
| 2021 FY | 159.62 Million CNY | 261.99% |
| 2021 Q2 | 102.43 Million CNY | 0.83% |
| 2020 Q1 | -173.33 Million CNY | -43.2% |
| 2020 FY | -98.53 Million CNY | 18.59% |
| 2020 Q4 | -98.53 Million CNY | 0.0% |
| 2020 Q3 | -98.53 Million CNY | 43.15% |
| 2020 Q2 | -173.33 Million CNY | 0.0% |
| 2019 Q3 | -121.04 Million CNY | 19.71% |
| 2019 Q1 | -150.75 Million CNY | 59.38% |
| 2019 Q2 | -150.75 Million CNY | 0.0% |
| 2019 FY | -121.04 Million CNY | 67.38% |
| 2019 Q4 | -121.04 Million CNY | 0.0% |
| 2018 Q2 | -77.62 Million CNY | 0.0% |
| 2018 Q4 | -371.1 Million CNY | 0.0% |
| 2018 Q3 | -371.1 Million CNY | -378.07% |
| 2018 FY | -371.1 Million CNY | -347.0% |
| 2018 Q1 | -77.62 Million CNY | 6.5% |
| 2017 Q1 | 244.39 Million CNY | -31.41% |
| 2017 Q4 | -83.02 Million CNY | 0.0% |
| 2017 FY | -83.02 Million CNY | -123.3% |
| 2016 Q4 | 356.28 Million CNY | 0.0% |
| 2016 FY | 356.28 Million CNY | -52.73% |
| 2015 FY | 753.69 Million CNY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Pak Fah Yeow International Limited | -258.7 Million HKD | 219.545% |
| Grand Pharmaceutical Group Limited | 2.03 Billion HKD | 84.779% |
| Extrawell Pharmaceutical Holdings Limited | 5.94 Million HKD | -5102.995% |
| Wai Yuen Tong Medicine Holdings Limited | 301.53 Million HKD | -2.564% |
| Qianhai Health Holdings Limited | -19.03 Million HKD | 1724.467% |
| Lee's Pharmaceutical Holdings Limited | 30.94 Million HKD | -899.309% |
| Essex Bio-Technology Limited | -219.22 Million HKD | 241.07% |
| Tongfang Kontafarma Holdings Limited | 256.16 Million HKD | -20.73% |
| PuraPharm Corporation Limited | 377.54 Million HKD | 18.086% |
| SSY Group Limited | 1.71 Billion HKD | 81.951% |
| JBM (Healthcare) Limited | -7.39 Million HKD | 4279.835% |
| Jacobson Pharma Corporation Limited | 337.44 Million HKD | 8.35% |
| China Resources Pharmaceutical Group Limited | 50.97 Billion HKD | 99.393% |